{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:10Z","timestamp":1791499630808,"version":"4.3.4"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072835"],"award-info":[{"award-number":["82072835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01216-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:27:28Z","timestamp":1776698848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments"],"prefix":"10.1007","volume":"49","author":[{"given":"Runsen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"1216_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"R.L. Siegel, T.B. Kratzer, A.N. Giaquinto, H. Sung, A. Jemal, Cancer statistics, 2025. CA Cancer J. Clin. 75(1), 10\u201345 (2025). https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J. Clin."},{"key":"1216_CR2","doi-asserted-by":"publisher","unstructured":"R.L. Siegel, A.N. Giaquinto, A. Jemal, Cancer statistics, 2024. CA Cancer J. Clin. 74(1):12\u201349 (2024). https:\/\/doi.org\/10.3322\/caac.21820","DOI":"10.3322\/caac.21820"},{"key":"1216_CR3","doi-asserted-by":"crossref","unstructured":"M. Gerlinger, D. Endesfelder, A. Stewart et al., Intratumor heterogeneity and branched evolution revealed by Multiregion Sequencing. N. Engl. J. Med. (2012)","DOI":"10.3410\/f.14001976.792252863"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41467-019-09255-1","volume":"10","author":"T Yan","year":"2019","unstructured":"T. Yan, H. Cui, Y. Zhou et al., Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat. Commun. 10, 1670 (2019). https:\/\/doi.org\/10.1038\/s41467-019-09255-1","journal-title":"Nat. Commun."},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41467-019-10877-8","volume":"10","author":"X Hu","year":"2019","unstructured":"X. Hu, J. Fujimoto, L. Ying et al., Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat. Commun. 10, 2978 (2019). https:\/\/doi.org\/10.1038\/s41467-019-10877-8","journal-title":"Nat. Commun."},{"issue":"4","key":"1216_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-018-0683-0","volume":"20","author":"GJ Morrison","year":"2018","unstructured":"G.J. Morrison, A. Goldkorn, Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Curr. Oncol. Rep. 20(4), 35 (2018). https:\/\/doi.org\/10.1007\/s11912-018-0683-0","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"1216_CR7","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/cancers13112652","volume":"13","author":"M Oshi","year":"2021","unstructured":"M. Oshi, V. Murthy, H. Takahashi et al., Urine as a Source of Liquid Biopsy for Cancer. Cancers. 13(11), 2652 (2021). https:\/\/doi.org\/10.3390\/cancers13112652","journal-title":"Cancers"},{"issue":"4","key":"1216_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/cancers14040969","volume":"14","author":"NK Ibrahim","year":"2022","unstructured":"N.K. Ibrahim, A. Eraky, J. Eggers et al., Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Cancers. 14(4), 969 (2022). https:\/\/doi.org\/10.3390\/cancers14040969","journal-title":"Cancers"},{"issue":"1","key":"1216_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"M. Nikanjam, S. Kato, R. Kurzrock, Liquid biopsy: current technology and clinical applications. J. Hematol. OncolJ Hematol. Oncol. 15(1), 131 (2022). https:\/\/doi.org\/10.1186\/s13045-022-01351-y","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"issue":"8","key":"1216_CR10","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/diagnostics11081391","volume":"11","author":"B Michela","year":"2021","unstructured":"B. Michela, Liquid Biopsy, A Family of Possible Diagnostic Tools. Diagnostics. 11(8), 1391 (2021). https:\/\/doi.org\/10.3390\/diagnostics11081391","journal-title":"Diagnostics"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.csbj.2016.05.004","volume":"14","author":"S Rapisuwon","year":"2016","unstructured":"S. Rapisuwon, E.E. Vietsch, A. Wellstein, Circulating biomarkers to monitor cancer progression and treatment. Comput. Struct. Biotechnol. J. 14, 211\u2013222 (2016). https:\/\/doi.org\/10.1016\/j.csbj.2016.05.004","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"104237","DOI":"10.1016\/j.ebiom.2022.104237","volume":"83","author":"Z Deng","year":"2022","unstructured":"Z. Deng, S. Wu, Y. Wang, D. Shi, Circulating tumor cell isolation for cancer diagnosis and prognosis. Ebiomedicine. 83, 104237 (2022). https:\/\/doi.org\/10.1016\/j.ebiom.2022.104237","journal-title":"Ebiomedicine"},{"issue":"11","key":"1216_CR13","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1002\/ijc.33386","volume":"148","author":"S Li","year":"2021","unstructured":"S. Li, M. Yi, B. Dong, X. Tan, S. Luo, K. Wu, The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int. J. Cancer. 148(11), 2640\u20132651 (2021). https:\/\/doi.org\/10.1002\/ijc.33386","journal-title":"Int. J. Cancer"},{"issue":"4","key":"1216_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"J.C.M. Wan, C. Massie, J. Garcia-Corbacho et al., Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer. 17(4), 223\u2013238 (2017). https:\/\/doi.org\/10.1038\/nrc.2017.7","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"1216_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/1878-0261.12859","volume":"15","author":"M Antunes-Ferreira","year":"2021","unstructured":"M. Antunes-Ferreira, D. Koppers\u2010Lalic, T. W\u00fcrdinger, Circulating platelets as liquid biopsy sources for cancer detection. Mol. Oncol. 15(6), 1727\u20131743 (2021). https:\/\/doi.org\/10.1002\/1878-0261.12859","journal-title":"Mol. Oncol."},{"key":"1216_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trsl.2017.04.002","volume":"185","author":"A Kowalik","year":"2017","unstructured":"A. Kowalik, M. Kowalewska, S. G\u00f3\u017ad\u017a, Current approaches for avoiding the limitations of circulating tumor cells detection methods\u2014implications for diagnosis and treatment of patients with solid tumors. Transl Res. 185, 58\u201384e15 (2017). https:\/\/doi.org\/10.1016\/j.trsl.2017.04.002","journal-title":"Transl Res."},{"issue":"10","key":"1216_CR17","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/cancers12103065","volume":"12","author":"N Sawabata","year":"2020","unstructured":"N. Sawabata, Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers. 12(10), 3065 (2020). https:\/\/doi.org\/10.3390\/cancers12103065","journal-title":"Cancers"},{"issue":"1","key":"1216_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","volume":"59","author":"C Alix-Panabieres","year":"2013","unstructured":"C. Alix-Panabieres, K. Pantel, Circulating Tumor Cells: Liquid Biopsy of Cancer. Clin. Chem. 59(1), 110\u2013118 (2013). https:\/\/doi.org\/10.1373\/clinchem.2012.194258","journal-title":"Clin. Chem."},{"issue":"9","key":"1216_CR19","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cancers12092361","volume":"12","author":"R Agashe","year":"2020","unstructured":"R. Agashe, R. Kurzrock, Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers. 12(9), 2361 (2020). https:\/\/doi.org\/10.3390\/cancers12092361","journal-title":"Cancers"},{"issue":"19","key":"1216_CR20","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.3390\/cancers14194753","volume":"14","author":"PF Geus","year":"2022","unstructured":"P.F. Geus, F. Hehnen, S. Krakowski et al., Verification of a Novel Minimally Invasive Device for the Isolation of Rare Circulating Tumor Cells (CTC) in Cancer Patients\u2019 Blood. Cancers. 14(19), 4753 (2022). https:\/\/doi.org\/10.3390\/cancers14194753","journal-title":"Cancers"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"114589","DOI":"10.1016\/j.bcp.2021.114589","volume":"188","author":"DJ Smit","year":"2021","unstructured":"D.J. Smit, K. Pantel, M. Juecker, Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy. Biochem. Pharmacol. 188, 114589 (2021). https:\/\/doi.org\/10.1016\/j.bcp.2021.114589","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"1216_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jmoldx.2015.02.001","volume":"17","author":"B Gold","year":"2015","unstructured":"B. Gold, M. Cankovic, L.V. Furtado, F. Meier, C.D. Gocke, Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility? A Report of the Association for Molecular Pathology. J. Mol. Diagn. 17(3), 209\u2013224 (2015). https:\/\/doi.org\/10.1016\/j.jmoldx.2015.02.001","journal-title":"J. Mol. Diagn."},{"key":"1216_CR23","doi-asserted-by":"publisher","first-page":"7149686","DOI":"10.1155\/2022\/7149686","volume":"2022","author":"S Wu","year":"2022","unstructured":"S. Wu, S. Zhao, D. Cui, J. Xie, Advances in the Biology, Detection Techniques, and Clinical Applications of Circulating Tumor Cells. J. Oncol. 2022, 7149686 (2022). https:\/\/doi.org\/10.1155\/2022\/7149686","journal-title":"J. Oncol."},{"issue":"3","key":"1216_CR24","doi-asserted-by":"publisher","first-page":"031501","DOI":"10.1063\/5.0093806","volume":"6","author":"C Macaraniag","year":"2022","unstructured":"C. Macaraniag, Q. Luan, J. Zhou, I. Papautsky, Microfluidic techniques for isolation, formation, and characterization of circulating tumor cells and clusters. Apl Bioeng. 6(3), 031501 (2022). https:\/\/doi.org\/10.1063\/5.0093806","journal-title":"Apl Bioeng."},{"issue":"4","key":"1216_CR25","first-page":"1659","volume":"61","author":"S Jahr","year":"2001","unstructured":"S. Jahr, H. Hentze, S. Englisch et al., DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659\u20131665 (2001)","journal-title":"Cancer Res."},{"issue":"12","key":"1216_CR26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/1878-0261.12144","volume":"11","author":"R Bayraktar","year":"2017","unstructured":"R. Bayraktar, Van K. Roosbroeck, G.A. Calin, Cell-to-cell communication: microRNAs as hormones. Mol. Oncol. 11(12), 1673\u20131686 (2017). https:\/\/doi.org\/10.1002\/1878-0261.12144","journal-title":"Mol. Oncol."},{"issue":"18","key":"1216_CR27","doi-asserted-by":"publisher","first-page":"6827","DOI":"10.3390\/ijms21186827","volume":"21","author":"M Szil\u00e1gyi","year":"2020","unstructured":"M. Szil\u00e1gyi, O. P\u00f6s, \u00c9. M\u00e1rton et al., Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int. J. Mol. Sci. 21(18), 6827 (2020). https:\/\/doi.org\/10.3390\/ijms21186827","journal-title":"Int. J. Mol. Sci."},{"issue":"43","key":"1216_CR28","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1039\/C9TB01490J","volume":"7","author":"N Soda","year":"2019","unstructured":"N. Soda, B.H.A. Rehm, P. Sonar, N.T. Nguyen, M.J.A. Shiddiky, Advanced liquid biopsy technologies for circulating biomarker detection. J. Mater. Chem. B 7(43), 6670\u20136704 (2019). https:\/\/doi.org\/10.1039\/C9TB01490J","journal-title":"J. Mater. Chem. B"},{"issue":"17","key":"1216_CR29","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.7150\/thno.44634","volume":"10","author":"CK Chen","year":"2020","unstructured":"C.K. Chen, J. Liao, M.S. Li, B.L. Khoo, Urine biopsy technologies: Cancer and beyond. Theranostics. 10(17), 7872\u20137888 (2020). https:\/\/doi.org\/10.7150\/thno.44634","journal-title":"Theranostics"},{"issue":"6","key":"1216_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","volume":"36","author":"DG Stover","year":"2018","unstructured":"D.G. Stover, H.A. Parsons, G. Ha et al., Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J. Clin. Oncol. 36(6), 543\u2013553 (2018). https:\/\/doi.org\/10.1200\/JCO.2017.76.0033","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"1216_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000226740","volume":"46","author":"M Stroun","year":"1989","unstructured":"M. Stroun, P. Anker, P. Maurice, J. Lyautey, C. Lederrey, M. Beljanski, Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 46(5), 318\u2013322 (1989). https:\/\/doi.org\/10.1159\/000226740","journal-title":"Oncology"},{"issue":"1","key":"1216_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Z.R. Reichert, T.M. Morgan, G. Li et al., Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. 34(1), 111\u2013120 (2023). https:\/\/doi.org\/10.1016\/j.annonc.2022.09.163","journal-title":"Ann. Oncol."},{"issue":"17","key":"1216_CR33","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.3390\/cancers14174281","volume":"14","author":"R Kurzrock","year":"2022","unstructured":"R. Kurzrock, C. Aggarwal, C. Weipert et al., Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations. Cancers. 14(17), 4281 (2022). https:\/\/doi.org\/10.3390\/cancers14174281","journal-title":"Cancers"},{"issue":"9","key":"1216_CR34","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41585-025-01023-9","volume":"22","author":"SV Lindskrog","year":"2025","unstructured":"S.V. Lindskrog, T. Strandgaard, I. Nordentoft et al., Circulating tumour DNA and circulating tumour cells in bladder cancer \u2014 from discovery to clinical implementation. Nat. Rev. Urol. 22(9), 590\u2013608 (2025). https:\/\/doi.org\/10.1038\/s41585-025-01023-9","journal-title":"Nat. Rev. Urol."},{"issue":"7732","key":"1216_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"S.Y. Shen, R. Singhania, G. Fehringer et al., Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 563(7732), 579\u2013583 (2018). https:\/\/doi.org\/10.1038\/s41586-018-0703-0","journal-title":"Nature"},{"issue":"1","key":"1216_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40246-019-0220-8","volume":"13","author":"M Chen","year":"2019","unstructured":"M. Chen, H. Zhao, Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum. Genomics. 13(1), 34 (2019). https:\/\/doi.org\/10.1186\/s40246-019-0220-8","journal-title":"Hum. Genomics"},{"issue":"12","key":"1216_CR37","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3390\/cancers16122280","volume":"16","author":"MB Gerke","year":"2024","unstructured":"M.B. Gerke, C.S. Jansen, M.A. Bilen, Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers. 16(12), 2280 (2024). https:\/\/doi.org\/10.3390\/cancers16122280","journal-title":"Cancers"},{"issue":"11","key":"1216_CR38","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/cancers16112001","volume":"16","author":"T Rendek","year":"2024","unstructured":"T. Rendek, O. Pos, T. Duranova et al., Current Challenges of Methylation-Based Liquid Biopsies in Cancer Diagnostics. Cancers. 16(11), 2001 (2024). https:\/\/doi.org\/10.3390\/cancers16112001","journal-title":"Cancers"},{"issue":"7","key":"1216_CR39","doi-asserted-by":"publisher","first-page":"105323","DOI":"10.1016\/j.esmoop.2025.105323","volume":"10","author":"YL Peng","year":"2025","unstructured":"Y.L. Peng, B. Yu, T.X. Huang et al., Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics-based liquid biopsy assay. ESMO Open. 10(7), 105323 (2025). https:\/\/doi.org\/10.1016\/j.esmoop.2025.105323","journal-title":"ESMO Open."},{"issue":"3","key":"1216_CR40","doi-asserted-by":"publisher","first-page":"e71019","DOI":"10.1111\/jcmm.71019","volume":"30","author":"H Kamli","year":"2026","unstructured":"H. Kamli, N.U. Khan, Emerging Role of ctDNA Fragmentomics and Epigenetic Signatures in the Early Detection, Minimal Residual Disease Assessment, and Precision Monitoring of Renal Cell Carcinoma. J. Cell. Mol. Med. 30(3), e71019 (2026). https:\/\/doi.org\/10.1111\/jcmm.71019","journal-title":"J. Cell. Mol. Med."},{"issue":"7","key":"1216_CR41","doi-asserted-by":"publisher","first-page":"100646","DOI":"10.1016\/j.medj.2025.100646","volume":"6","author":"MJL Ma","year":"2025","unstructured":"M.J.L. Ma, W.Z. Zhang, P. Jiang et al., Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnostics. Med. 6(7), 100646 (2025). https:\/\/doi.org\/10.1016\/j.medj.2025.100646","journal-title":"Med"},{"key":"1216_CR42","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jlb.2025.100311","volume":"9","author":"DW Brown","year":"2025","unstructured":"D.W. Brown, D. Sun, A.D. Fine et al., Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy. J. Liq Biopsy. 9, 100311 (2025). https:\/\/doi.org\/10.1016\/j.jlb.2025.100311","journal-title":"J. Liq Biopsy"},{"issue":"8","key":"1216_CR43","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ijms17081278","volume":"17","author":"P Koczera","year":"2016","unstructured":"P. Koczera, L. Martin, G. Marx, T. Schuerholz, The Ribonuclease A Superfamily in Humans: Canonical RNases as the Buttress of Innate Immunity. Int. J. Mol. Sci. 17(8), 1278 (2016). https:\/\/doi.org\/10.3390\/ijms17081278","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"1216_CR44","doi-asserted-by":"publisher","first-page":"1506198","DOI":"10.1080\/20013078.2018.1506198","volume":"7","author":"RM Allen","year":"2018","unstructured":"R.M. Allen, S. Zhao, M.A. Ramirez Solano et al., Bioinformatic analysis of endogenous and exogenous small RNAs on lipoproteins. J. Extracell. Vesicles. 7(1), 1506198 (2018). https:\/\/doi.org\/10.1080\/20013078.2018.1506198","journal-title":"J. Extracell. Vesicles"},{"issue":"6","key":"1216_CR45","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/ATVBAHA.112.300741","volume":"33","author":"J Wagner","year":"2013","unstructured":"J. Wagner, M. Riwanto, C. Besler et al., Characterization of Levels and Cellular Transfer of Circulating Lipoprotein-Bound MicroRNAs. Arterioscler. Thromb. Vasc Biol. 33(6), 1392\u20131400 (2013). https:\/\/doi.org\/10.1161\/ATVBAHA.112.300741","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"10","key":"1216_CR46","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","volume":"48","author":"NB Tsui","year":"2002","unstructured":"N.B. Tsui, E.K. Ng, Y.D. Lo, Stability of Endogenous and Added RNA in Blood Specimens, Serum, and Plasma. Clin. Chem. 48(10), 1647\u20131653 (2002). https:\/\/doi.org\/10.1093\/clinchem\/48.10.1647","journal-title":"Clin. Chem."},{"issue":"5","key":"1216_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/sj.leu.2404132","volume":"20","author":"J Ratajczak","year":"2006","unstructured":"J. Ratajczak, K. Miekus, M. Kucia et al., Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 20(5), 847\u2013856 (2006). https:\/\/doi.org\/10.1038\/sj.leu.2404132","journal-title":"Leukemia"},{"issue":"5","key":"1216_CR48","doi-asserted-by":"publisher","first-page":"e1791","DOI":"10.1002\/wrna.1791","volume":"14","author":"S Xing","year":"2023","unstructured":"S. Xing, Y. Zhu, Y. You et al., Cell-free RNA for the liquid biopsy of gastrointestinal cancer. WIREs RNA 14(5), e1791 (2023). https:\/\/doi.org\/10.1002\/wrna.1791","journal-title":"WIREs RNA"},{"issue":"2","key":"1216_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cell.2019.03.023","volume":"177","author":"S Das","year":"2019","unstructured":"S. Das, K.M. Ansel, M. Bitzer et al., The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell. 177(2), 231\u2013242 (2019). https:\/\/doi.org\/10.1016\/j.cell.2019.03.023","journal-title":"Cell"},{"issue":"5","key":"1216_CR50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","volume":"179","author":"FJ Slack","year":"2019","unstructured":"F.J. Slack, A.M. Chinnaiyan, The Role of Non-coding RNAs in Oncology. Cell. 179(5), 1033\u20131055 (2019). https:\/\/doi.org\/10.1016\/j.cell.2019.10.017","journal-title":"Cell"},{"issue":"3","key":"1216_CR51","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.bbrc.2018.04.120","volume":"500","author":"T Ishiba","year":"2018","unstructured":"T. Ishiba, A.C. Hoffmann, J. Usher et al., Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem. Biophys. Res. Commun. 500(3), 621\u2013625 (2018). https:\/\/doi.org\/10.1016\/j.bbrc.2018.04.120","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"1216_CR52","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.4049\/jimmunol.1900375","volume":"203","author":"DC Zawieja","year":"2019","unstructured":"D.C. Zawieja, S. Thangaswamy, W. Wang et al., Lymphatic Cannulation for Lymph Sampling and Molecular Delivery. J. Immunol. 203(8), 2339\u20132350 (2019). https:\/\/doi.org\/10.4049\/jimmunol.1900375","journal-title":"J. Immunol."},{"issue":"5","key":"1216_CR53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/cyto.a.24221","volume":"99","author":"M Han","year":"2021","unstructured":"M. Han, J.A. Watts, A. Jamshidi-Parsian et al., Lymph Liquid Biopsy for Detection of Cancer Stem Cells. Cytometry A 99(5), 496\u2013502 (2021). https:\/\/doi.org\/10.1002\/cyto.a.24221","journal-title":"Cytometry A"},{"issue":"2","key":"1216_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1208\/s12248-021-00554-4","volume":"23","author":"A Srivastava","year":"2021","unstructured":"A. Srivastava, S. Rathore, A. Munshi, R. Ramesh, Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. AAPS J. 23(2), 30 (2021). https:\/\/doi.org\/10.1208\/s12248-021-00554-4","journal-title":"AAPS J."},{"issue":"1","key":"1216_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1479-5876-10-5","volume":"10","author":"JM Street","year":"2012","unstructured":"J.M. Street, P.E. Barran, C.L. Mackay et al., Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J. Transl Med. 10(1), 5 (2012). https:\/\/doi.org\/10.1186\/1479-5876-10-5","journal-title":"J. Transl Med."},{"issue":"4","key":"1216_CR56","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI81135","volume":"126","author":"R Kalluri","year":"2016","unstructured":"R. Kalluri, The biology and function of exosomes in cancer. J. Clin. Invest. 126(4), 1208\u20131215 (2016). https:\/\/doi.org\/10.1172\/JCI81135","journal-title":"J. Clin. Invest."},{"key":"1216_CR57","doi-asserted-by":"publisher","first-page":"340703","DOI":"10.1016\/j.aca.2022.340703","volume":"1244","author":"S He","year":"2023","unstructured":"S. He, L. Ding, H. Yuan, G. Zhao, X. Yang, Y. Wu, A review of sensors for classification and subtype discrimination of cancer: Insights into circulating tumor cells and tumor-derived extracellular vesicles. Anal. Chim. Acta. 1244, 340703 (2023). https:\/\/doi.org\/10.1016\/j.aca.2022.340703","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"1216_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-022-01509-9","volume":"21","author":"D Yu","year":"2022","unstructured":"D. Yu, Y. Li, M. Wang et al., Exosomes as a new frontier of cancer liquid biopsy. Mol. Cancer. 21(1), 56 (2022). https:\/\/doi.org\/10.1186\/s12943-022-01509-9","journal-title":"Mol. Cancer"},{"issue":"1","key":"1216_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-019-1001-7","volume":"18","author":"M Fu","year":"2019","unstructured":"M. Fu, J. Gu, P. Jiang, H. Qian, W. Xu, X. Zhang, Exosomes in gastric cancer: roles, mechanisms, and applications. Mol. Cancer. 18(1), 41 (2019). https:\/\/doi.org\/10.1186\/s12943-019-1001-7","journal-title":"Mol. Cancer"},{"issue":"7","key":"1216_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/cells8070688","volume":"8","author":"M Nimir","year":"2019","unstructured":"M. Nimir, Y. Ma, S.A. Jeffreys et al., Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes. Cells. 8(7), 688 (2019). https:\/\/doi.org\/10.3390\/cells8070688","journal-title":"Cells"},{"issue":"3","key":"1216_CR61","doi-asserted-by":"publisher","first-page":"2001131","DOI":"10.1002\/smtd.202001131","volume":"5","author":"B Lin","year":"2021","unstructured":"B. Lin, Y. Lei, J. Wang et al., Microfluidic-Based Exosome Analysis for Liquid Biopsy. Small Methods. 5(3), 2001131 (2021). https:\/\/doi.org\/10.1002\/smtd.202001131","journal-title":"Small Methods"},{"key":"1216_CR62","unstructured":"I. Bertolini, A. Terrasi, C. Martelli et al., A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomes"},{"issue":"5","key":"1216_CR63","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ajpath.2012.07.030","volume":"181","author":"D Di Vizio","year":"2012","unstructured":"Di D. Vizio, M. Morello, A.C. Dudley et al., Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. Am. J. Pathol. 181(5), 1573\u20131584 (2012). https:\/\/doi.org\/10.1016\/j.ajpath.2012.07.030","journal-title":"Am. J. Pathol."},{"issue":"10","key":"1216_CR64","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/biomedicines12102359","volume":"12","author":"V Magri","year":"2024","unstructured":"V. Magri, L. Marino, Del F. Giudice et al., Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients. Biomedicines. 12(10), 2359 (2024). https:\/\/doi.org\/10.3390\/biomedicines12102359","journal-title":"Biomedicines"},{"issue":"1","key":"1216_CR65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12959-018-0170-8","volume":"16","author":"M Seyoum","year":"2018","unstructured":"M. Seyoum, B. Enawgaw, M. Melku, Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens. Thromb. J. 16(1), 16 (2018). https:\/\/doi.org\/10.1186\/s12959-018-0170-8","journal-title":"Thromb. J."},{"issue":"13","key":"1216_CR66","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","volume":"118","author":"RJA Nilsson","year":"2011","unstructured":"R.J.A. Nilsson, L. Balaj, E. Hulleman et al., Blood platelets contain tumor-derived RNA biomarkers. Blood. 118(13), 3680\u20133683 (2011). https:\/\/doi.org\/10.1182\/blood-2011-03-344408","journal-title":"Blood"},{"issue":"5","key":"1216_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1752-8062.2010.00226.x","volume":"3","author":"DC Calverley","year":"2010","unstructured":"D.C. Calverley, T.L. Phang, Q.G. Choudhury et al., Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer. Clin. Transl Sci. 3(5), 227\u2013232 (2010). https:\/\/doi.org\/10.1111\/j.1752-8062.2010.00226.x","journal-title":"Clin. Transl Sci."},{"issue":"22","key":"1216_CR68","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1182\/blood-2018-12-852830","volume":"133","author":"T In","year":"2019","unstructured":"T. In, S.G.J.G. Veld, T. Wurdinger, Tumor-educated platelets. Blood. 133(22), 2359\u20132364 (2019). https:\/\/doi.org\/10.1182\/blood-2018-12-852830","journal-title":"Blood"},{"key":"1216_CR69","doi-asserted-by":"publisher","first-page":"102863","DOI":"10.1016\/j.critrevonc.2020.102863","volume":"146","author":"L Liu","year":"2020","unstructured":"L. Liu, F. Lin, X. Ma, Z. Chen, J. Yu, Tumor-educated platelet as liquid biopsy in lung cancer patients. Crit. Rev. Oncol. Hematol. 146, 102863 (2020). https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102863","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"1216_CR70","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.celrep.2018.03.092","volume":"23","author":"Y Ward","year":"2018","unstructured":"Y. Ward, R. Lake, F. Faraji et al., Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration. Cell. Rep. 23(3), 808\u2013822 (2018). https:\/\/doi.org\/10.1016\/j.celrep.2018.03.092","journal-title":"Cell. Rep."},{"issue":"2","key":"1216_CR71","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"T. Placke, M. \u00d6rgel, M. Schaller et al., Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells. Cancer Res. 72(2), 440\u2013448 (2012). https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1872","journal-title":"Cancer Res."},{"key":"1216_CR72","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fonc.2020.00778","volume":"10","author":"M Provenzano","year":"2020","unstructured":"M. Provenzano, A.K. Allayeh, Liquid Biopsy to Detect DNA\/RNA Based Markers of Small DNA Oncogenic Viruses for Prostate Cancer Diagnosis, Prognosis, and Prediction. Front. Oncol. 10, 778 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.00778","journal-title":"Front. Oncol."},{"issue":"1","key":"1216_CR73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"R. Hu, T.A. Dunn, S. Wei et al., Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. Cancer Res. 69(1), 16\u201322 (2009). https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2764","journal-title":"Cancer Res."},{"issue":"16","key":"1216_CR74","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","volume":"23","author":"M Kohli","year":"2017","unstructured":"M. Kohli, Y. Ho, D.W. Hillman et al., Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin. Cancer Res. 23(16), 4704\u20134715 (2017). https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"1216_CR75","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pros.24469","volume":"83","author":"MP Fernandez-Perez","year":"2023","unstructured":"M.P. Fernandez-Perez, E. Perez\u2010Navarro, T. Alonso\u2010Gordoa et al., A correlative biomarker study and integrative prognostic model in chemotherapy\u2010na\u00efve metastatic castration\u2010resistant prostate cancer treated with enzalutamide. Prostate. 83(4), 376\u2013384 (2023). https:\/\/doi.org\/10.1002\/pros.24469","journal-title":"Prostate"},{"issue":"12","key":"1216_CR76","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","volume":"33","author":"HI Scher","year":"2015","unstructured":"H.I. Scher, G. Heller, A. Molina et al., Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. J. Clin. Oncol. 33(12), 1348\u20131355 (2015). https:\/\/doi.org\/10.1200\/JCO.2014.55.3487","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"1216_CR77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/pros.23452","volume":"78","author":"HH Cheng","year":"2018","unstructured":"H.H. Cheng, M. Plets, H. Li et al., Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate. 78(2), 121\u2013127 (2018). https:\/\/doi.org\/10.1002\/pros.23452","journal-title":"Prostate"},{"issue":"7","key":"1216_CR78","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/1078-0432.CCR-20-3587","volume":"27","author":"A Goldkorn","year":"2021","unstructured":"A. Goldkorn, C. Tangen, M. Plets et al., Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin. Cancer Res. 27(7), 1967\u20131973 (2021). https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3587","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"1216_CR79","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1158\/1535-7163.MCT-22-0020","volume":"21","author":"U Swami","year":"2022","unstructured":"U. Swami, N. Sayegh, Y. Jo et al., External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol. Cancer Ther. 21(12), 1857\u20131861 (2022). https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0020","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"1216_CR80","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","volume":"26","author":"KH Stopsack","year":"2020","unstructured":"K.H. Stopsack, S. Nandakumar, A.G. Wibmer et al., Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clin. Cancer Res. 26(13), 3230\u20133238 (2020). https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0168","journal-title":"Clin. Cancer Res."},{"key":"1216_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.trsl.2018.05.004","volume":"201","author":"I Bin Riaz","year":"2018","unstructured":"I. Bin Riaz, L. Wang, M. Kohli, Liquid biopsy approach in the management of prostate cancer. Transl Res. 201, 60\u201370 (2018). https:\/\/doi.org\/10.1016\/j.trsl.2018.05.004","journal-title":"Transl Res."},{"issue":"10","key":"1216_CR82","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s11912-022-01278-0","volume":"24","author":"V Tulpule","year":"2022","unstructured":"V. Tulpule, G.J. Morrison, M. Falcone, D.I. Quinn, A. Goldkorn, Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Curr. Oncol. Rep. 24(10), 1287\u20131298 (2022). https:\/\/doi.org\/10.1007\/s11912-022-01278-0","journal-title":"Curr. Oncol. Rep."},{"issue":"18","key":"1216_CR83","doi-asserted-by":"publisher","first-page":"16411","DOI":"10.18632\/oncotarget.3845","volume":"6","author":"S Xia","year":"2015","unstructured":"S. Xia, M. Kohli, M. Du et al., Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 6(18), 16411\u201316421 (2015). https:\/\/doi.org\/10.18632\/oncotarget.3845","journal-title":"Oncotarget"},{"issue":"8","key":"1216_CR84","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14737159.2016.1197121","volume":"16","author":"W He","year":"2016","unstructured":"W. He, K.S. Bishop, The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer. Expert Rev. Mol. Diagn. 16(8), 839\u2013852 (2016). https:\/\/doi.org\/10.1080\/14737159.2016.1197121","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"3","key":"1216_CR85","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/bjc.2015.240","volume":"113","author":"IM Reis","year":"2015","unstructured":"I.M. Reis, K. Ramachandran, C. Speer, E. Gordian, R. Singal, Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. Br. J. Cancer. 113(3), 460\u2013468 (2015). https:\/\/doi.org\/10.1038\/bjc.2015.240","journal-title":"Br. J. Cancer"},{"issue":"1","key":"1216_CR86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/bjc.2011.143","volume":"105","author":"T Wu","year":"2011","unstructured":"T. Wu, E. Giovannucci, J. Welge, P. Mallick, W.Y. Tang, S.M. Ho, Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br. J. Cancer. 105(1), 65\u201373 (2011). https:\/\/doi.org\/10.1038\/bjc.2011.143","journal-title":"Br. J. Cancer"},{"issue":"24","key":"1216_CR87","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.3390\/cancers14246094","volume":"14","author":"S Eickelschulte","year":"2022","unstructured":"S. Eickelschulte, A.L. Riediger, A.K. Angeles et al., Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. Cancers. 14(24), 6094 (2022). https:\/\/doi.org\/10.3390\/cancers14246094","journal-title":"Cancers"},{"key":"1216_CR88","doi-asserted-by":"publisher","unstructured":"A. Romanel, D.G. Tandefelt, V. Conteduca et al., Plasma AR and abiraterone-resistant prostate cancer. Sci. Transl. Med. 7(312) (2015). https:\/\/doi.org\/10.1126\/scitranslmed.aac9511","DOI":"10.1126\/scitranslmed.aac9511"},{"issue":"12","key":"1216_CR89","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"A.W. Wyatt, A.A. Azad, S.V. Volik et al., Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol. 2(12), 1598 (2016). https:\/\/doi.org\/10.1001\/jamaoncol.2016.0494","journal-title":"JAMA Oncol."},{"issue":"2","key":"1216_CR90","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","volume":"80","author":"S Sumanasuriya","year":"2021","unstructured":"S. Sumanasuriya, G. Seed, H. Parr et al., Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur. Urol. 80(2), 243\u2013253 (2021). https:\/\/doi.org\/10.1016\/j.eururo.2021.05.030","journal-title":"Eur. Urol."},{"issue":"5suppl","key":"1216_CR91","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1200\/JCO.2025.43.5_suppl.402","volume":"43","author":"PD Zang","year":"2025","unstructured":"P.D. Zang, D. Lama, Z. Huang et al., Feasibility of enriched amplicon circulating tumor DNA sequencing to detect minimal residual disease (MRD) after prostatectomy in localized prostate cancer. J. Clin. Oncol. 43(5suppl), 402\u2013402 (2025). https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.402","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"1216_CR92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-020-00770-1","volume":"12","author":"E Lau","year":"2020","unstructured":"E. Lau, P. McCoy, F. Reeves et al., Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Med. 12(1), 72 (2020). https:\/\/doi.org\/10.1186\/s13073-020-00770-1","journal-title":"Genome Med."},{"issue":"10","key":"1216_CR93","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","volume":"21","author":"AA Azad","year":"2015","unstructured":"A.A. Azad, S.V. Volik, A.W. Wyatt et al., Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin. Cancer Res. 21(10), 2315\u20132324 (2015). https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2666","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"1216_CR94","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"C.J. Sweeney, R. Petry, C. Xu et al., Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res. 30(18), 4115\u20134122 (2024). https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1096","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"1216_CR95","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.3390\/cancers13133373","volume":"13","author":"M Matuszczak","year":"2021","unstructured":"M. Matuszczak, J.A. Schalken, M. Salagierski, Prostate Cancer Liquid Biopsy Biomarkers\u2019 Clinical Utility in Diagnosis and Prognosis. Cancers. 13(13), 3373 (2021). https:\/\/doi.org\/10.3390\/cancers13133373","journal-title":"Cancers"},{"issue":"2","key":"1216_CR96","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","volume":"39","author":"S Saini","year":"2016","unstructured":"S. Saini, PSA and beyond: alternative prostate cancer biomarkers. Cell. Oncol. 39(2), 97\u2013106 (2016). https:\/\/doi.org\/10.1007\/s13402-016-0268-6","journal-title":"Cell. Oncol."},{"issue":"3","key":"1216_CR97","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","volume":"69","author":"LS Marks","year":"2007","unstructured":"L.S. Marks, Y. Fradet, I. Lim Deras et al., PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. Urology. 69(3), 532\u2013535 (2007). https:\/\/doi.org\/10.1016\/j.urology.2006.12.014","journal-title":"Urology"},{"issue":"31","key":"1216_CR98","doi-asserted-by":"publisher","first-page":"50804","DOI":"10.18632\/oncotarget.15133","volume":"8","author":"M Alshalalfa","year":"2017","unstructured":"M. Alshalalfa, G.W. Verhaegh, E.A. Gibb et al., Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget. 8(31), 50804\u201350813 (2017). https:\/\/doi.org\/10.18632\/oncotarget.15133","journal-title":"Oncotarget"},{"issue":"42","key":"1216_CR99","doi-asserted-by":"publisher","first-page":"e12806","DOI":"10.1097\/MD.0000000000012806","volume":"97","author":"Z Mao","year":"2018","unstructured":"Z. Mao, A. Ji, K. Yang et al., Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer. Med. (Baltim). 97(42), e12806 (2018). https:\/\/doi.org\/10.1097\/MD.0000000000012806","journal-title":"Med. (Baltim)."},{"issue":"11","key":"1216_CR100","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/cts.13372","volume":"15","author":"S Derderian","year":"2022","unstructured":"S. Derderian, Q. Vesval, M.D. Wissing et al., Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clin. Transl Sci. 15(11), 2597\u20132612 (2022). https:\/\/doi.org\/10.1111\/cts.13372","journal-title":"Clin. Transl Sci."},{"issue":"7","key":"1216_CR101","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"J. McKiernan, M.J. Donovan, V. O\u2019Neill et al., A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2(7), 882 (2016). https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097","journal-title":"JAMA Oncol."},{"issue":"10","key":"1216_CR102","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/sj.bjc.6605058","volume":"100","author":"J Nilsson","year":"2009","unstructured":"J. Nilsson, J. Skog, A. Nordstrand et al., Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer. 100(10), 1603\u20131607 (2009). https:\/\/doi.org\/10.1038\/sj.bjc.6605058","journal-title":"Br. J. Cancer"},{"issue":"6","key":"1216_CR103","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","volume":"74","author":"J McKiernan","year":"2018","unstructured":"J. McKiernan, M.J. Donovan, E. Margolis et al., A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2\u201310 ng\/ml at Initial Biopsy. Eur. Urol. 74(6), 731\u2013738 (2018). https:\/\/doi.org\/10.1016\/j.eururo.2018.08.019","journal-title":"Eur. Urol."},{"key":"1216_CR104","unstructured":"J.V. Dudinec, S.M. Wang, S. Kotamarti, K.E. Morris, T.J. Polascik, J.W. Moul, Clinical utility of multiple secondary combined tests in prostate cancer screening. Can. J. Urol. (2023)."},{"issue":"6","key":"1216_CR105","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/10408363.2024.2309935","volume":"61","author":"\u00c1 Gonz\u00e1lez","year":"2024","unstructured":"\u00c1. Gonz\u00e1lez, S. L\u00f3pez-Borrego, A. Sand\u00faa, M. Vales-Gomez, E. Alegre, Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories. Crit. Rev. Clin. Lab. Sci. 61(6), 435\u2013457 (2024). https:\/\/doi.org\/10.1080\/10408363.2024.2309935","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"19","key":"1216_CR106","doi-asserted-by":"publisher","first-page":"14713","DOI":"10.3390\/ijms241914713","volume":"24","author":"TY Chen","year":"2023","unstructured":"T.Y. Chen, M. Mihalopoulos, L. Zuluaga et al., Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer. Int. J. Mol. Sci. 24(19), 14713 (2023). https:\/\/doi.org\/10.3390\/ijms241914713","journal-title":"Int. J. Mol. Sci."},{"issue":"51","key":"1216_CR107","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.18632\/oncotarget.27849","volume":"11","author":"D Bhagirath","year":"2020","unstructured":"D. Bhagirath, T.L. Yang, T. Akoto, N. Patel, L.Z. Tabatabai, S. Saini, MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer. Oncotarget. 11(51), 4681\u20134692 (2020). https:\/\/doi.org\/10.18632\/oncotarget.27849","journal-title":"Oncotarget"},{"issue":"6","key":"1216_CR108","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.21037\/tau.2017.09.16","volume":"6","author":"S Riethdorf","year":"2017","unstructured":"S. Riethdorf, A. Soave, M. Rink, The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Transl Androl. Urol. 6(6), 1090\u20131110 (2017). https:\/\/doi.org\/10.21037\/tau.2017.09.16","journal-title":"Transl Androl. Urol."},{"issue":"2","key":"1216_CR109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/annonc\/mdn627","volume":"20","author":"DJ Gallagher","year":"2009","unstructured":"D.J. Gallagher, M.I. Milowsky, N. Ishill et al., Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol. 20(2), 305\u2013308 (2009). https:\/\/doi.org\/10.1093\/annonc\/mdn627","journal-title":"Ann. Oncol."},{"issue":"7","key":"1216_CR110","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/cncr.22543","volume":"109","author":"M Naoe","year":"2007","unstructured":"M. Naoe, Y. Ogawa, J. Morita et al., Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer. 109(7), 1439\u20131445 (2007). https:\/\/doi.org\/10.1002\/cncr.22543","journal-title":"Cancer"},{"issue":"4","key":"1216_CR111","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","volume":"61","author":"M Rink","year":"2012","unstructured":"M. Rink, F.K. Chun, R. Dahlem et al., Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur. Urol. 61(4), 810\u2013817 (2012). https:\/\/doi.org\/10.1016\/j.eururo.2012.01.017","journal-title":"Eur. Urol."},{"issue":"35","key":"1216_CR112","doi-asserted-by":"publisher","first-page":"59527","DOI":"10.18632\/oncotarget.18521","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Z. Zhang, W. Fan, Q. Deng et al., The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget. 8(35), 59527\u201359538 (2017). https:\/\/doi.org\/10.18632\/oncotarget.18521","journal-title":"Oncotarget"},{"issue":"13","key":"1216_CR113","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/cancers14133118","volume":"14","author":"C Amantini","year":"2022","unstructured":"C. Amantini, F. Maggi, J.A. De Rossi et al., The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer. Cancers. 14(13), 3118 (2022). https:\/\/doi.org\/10.3390\/cancers14133118","journal-title":"Cancers"},{"issue":"8","key":"1216_CR114","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/ijc.28830","volume":"135","author":"P Gazzaniga","year":"2014","unstructured":"P. Gazzaniga, De E. Berardinis, C. Raimondi et al., Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer: Influence of CTC on the Natural Course of Early Bladder Cancer. Int. J. Cancer. 135(8), 1978\u20131982 (2014). https:\/\/doi.org\/10.1002\/ijc.28830","journal-title":"Int. J. Cancer"},{"issue":"6","key":"1216_CR115","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5152\/tud.2025.24135","volume":"50","author":"A Zulfiqqar","year":"2025","unstructured":"A. Zulfiqqar, B. Liliana, N.L. Mataho, E. Subekti, The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Urol. Res. Pract. 50(6), 343\u2013350 (2025). https:\/\/doi.org\/10.5152\/tud.2025.24135","journal-title":"Urol. Res. Pract."},{"issue":"5","key":"1216_CR116","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1634\/theoncologist.2018-0784","volume":"24","author":"C Nicolazzo","year":"2019","unstructured":"C. Nicolazzo, G.M. Busetto, A. Gradilone et al., Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial. Oncologist. 24(5), 612\u2013616 (2019). https:\/\/doi.org\/10.1634\/theoncologist.2018-0784","journal-title":"Oncologist"},{"issue":"1","key":"1216_CR117","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euo.2020.09.003","volume":"4","author":"C Nicolazzo","year":"2021","unstructured":"C. Nicolazzo, De E. Berardinis, P. Gazzaniga, Liquid Biopsy for Predicting Bacillus Calmette-Gu\u00e9rin Unresponsiveness in Non\u2013muscle-invasive Bladder Cancer. Eur. Urol. Oncol. 4(1), 124\u2013125 (2021). https:\/\/doi.org\/10.1016\/j.euo.2020.09.003","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"1216_CR118","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.euf.2022.08.013","volume":"8","author":"L Groen","year":"2022","unstructured":"L. Groen, J. Schalken, Liquid Biopsy for Prostate and Bladder Cancer: Progress and Pitfalls. Eur. Urol. Focus. 8(4), 904\u2013906 (2022). https:\/\/doi.org\/10.1016\/j.euf.2022.08.013","journal-title":"Eur. Urol. Focus"},{"issue":"2","key":"1216_CR119","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.esmoop.2022.100416","volume":"7","author":"N Beije","year":"2022","unstructured":"N. Beije, De I.E. Kruijff, De J.J. Jong et al., Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open. 7(2), 100416 (2022). https:\/\/doi.org\/10.1016\/j.esmoop.2022.100416","journal-title":"ESMO Open."},{"issue":"1","key":"1216_CR120","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/tau.2018.11.05","volume":"8","author":"M Rink","year":"2019","unstructured":"M. Rink, H. Schwarzenbach, M.W. Vetterlein, S. Riethdorf, A. Soave, The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl Androl. Urol. 8(1), 61\u201375 (2019). https:\/\/doi.org\/10.21037\/tau.2018.11.05","journal-title":"Transl Androl. Urol."},{"issue":"2","key":"1216_CR121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4111\/icu.2016.57.2.106","volume":"57","author":"YH Kim","year":"2016","unstructured":"Y.H. Kim, C. Yan, I.S. Lee et al., Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer. Investig Clin. Urol. 57(2), 106 (2016). https:\/\/doi.org\/10.4111\/icu.2016.57.2.106","journal-title":"Investig Clin. Urol."},{"issue":"1","key":"1216_CR122","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12885-016-2748-5","volume":"16","author":"JP Roperch","year":"2016","unstructured":"J.P. Roperch, B. Grandchamp, F. Desgrandchamps et al., Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. 16(1), 704 (2016). https:\/\/doi.org\/10.1186\/s12885-016-2748-5","journal-title":"BMC Cancer"},{"issue":"6","key":"1216_CR123","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"E. Christensen, K. Birkenkamp-Demtr\u00f6der, I. Nordentoft et al., Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. Eur. Urol. 71(6), 961\u2013969 (2017). https:\/\/doi.org\/10.1016\/j.eururo.2016.12.016","journal-title":"Eur. Urol."},{"issue":"1","key":"1216_CR124","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-022-09616-y","volume":"22","author":"L Deng","year":"2022","unstructured":"L. Deng, H. Chao, H. Deng et al., A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer. BMC Cancer. 22(1), 510 (2022). https:\/\/doi.org\/10.1186\/s12885-022-09616-y","journal-title":"BMC Cancer"},{"issue":"1","key":"1216_CR125","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","volume":"23","author":"J Wu","year":"2024","unstructured":"J. Wu, Y. Lin, K. Yang et al., Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial. Mol. Cancer. 23(1), 57 (2024). https:\/\/doi.org\/10.1186\/s12943-024-01974-4","journal-title":"Mol. Cancer"},{"issue":"1","key":"1216_CR126","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"K. Birkenkamp-Demtr\u00f6der, I. Nordentoft, E. Christensen et al., Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur. Urol. 70(1), 75\u201382 (2016). https:\/\/doi.org\/10.1016\/j.eururo.2016.01.007","journal-title":"Eur. Urol."},{"issue":"18","key":"1216_CR127","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"E. Christensen, K. Birkenkamp-Demtr\u00f6der, H. Sethi et al., Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37(18), 1547\u20131557 (2019). https:\/\/doi.org\/10.1200\/JCO.18.02052","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"1216_CR128","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"K. Birkenkamp-Demtr\u00f6der, E. Christensen, I. Nordentoft et al., Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. Eur. Urol. 73(4), 535\u2013540 (2018). https:\/\/doi.org\/10.1016\/j.eururo.2017.09.011","journal-title":"Eur. Urol."},{"issue":"7528","key":"1216_CR129","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"T. Powles, J.P. Eder, G.D. Fine et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515(7528), 558\u2013562 (2014). https:\/\/doi.org\/10.1038\/nature13904","journal-title":"Nature"},{"key":"1216_CR130","doi-asserted-by":"publisher","first-page":"100310","DOI":"10.1016\/j.jlb.2025.100310","volume":"9","author":"F Crocetto","year":"2025","unstructured":"F. Crocetto, U. Amicuzi, M. Musone et al., Liquid Biopsy: Current advancements in clinical practice for bladder cancer. J. Liq Biopsy. 9, 100310 (2025). https:\/\/doi.org\/10.1016\/j.jlb.2025.100310","journal-title":"J. Liq Biopsy"},{"issue":"9","key":"1216_CR131","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","volume":"30","author":"T Powles","year":"2024","unstructured":"T. Powles, Y.H. Chang, Y. Yamamoto et al., Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial. Nat. Med. 30(9), 2508\u20132516 (2024). https:\/\/doi.org\/10.1038\/s41591-024-03091-7","journal-title":"Nat. Med."},{"issue":"4","key":"1216_CR132","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.29041","volume":"136","author":"X Jiang","year":"2015","unstructured":"X. Jiang, L. Du, L. Wang et al., Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int. J. Cancer. 136(4), 854\u2013862 (2015). https:\/\/doi.org\/10.1002\/ijc.29041","journal-title":"Int. J. Cancer"},{"issue":"1","key":"1216_CR133","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cas.13856","volume":"110","author":"W Usuba","year":"2019","unstructured":"W. Usuba, F. Urabe, Y. Yamamoto et al., Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 110(1), 408\u2013419 (2019). https:\/\/doi.org\/10.1111\/cas.13856","journal-title":"Cancer Sci."},{"key":"1216_CR134","doi-asserted-by":"publisher","unstructured":"Y. Yang, A. Qu, J. Liu et al., Serum miR-210 contributes to tumor detection, stage prediction and dynamic surveillance in patients with bladder cancer. Ray RB, ed. Plos One. 10(8):e0135168 (2015). https:\/\/doi.org\/10.1371\/journal.pone.0135168","DOI":"10.1371\/journal.pone.0135168"},{"issue":"8","key":"1216_CR135","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.urolonc.2012.06.010","volume":"31","author":"L Adam","year":"2013","unstructured":"L. Adam, M.F. Wszolek, C.G. Liu et al., Plasma microRNA profiles for bladder cancer detection. Urol. Oncol. Semin Orig Investig. 31(8), 1701\u20131708 (2013). https:\/\/doi.org\/10.1016\/j.urolonc.2012.06.010","journal-title":"Urol. Oncol. Semin Orig Investig"},{"issue":"1","key":"1216_CR136","doi-asserted-by":"publisher","first-page":"30919","DOI":"10.1038\/srep30919","volume":"6","author":"Z Zhong","year":"2016","unstructured":"Z. Zhong, M. Lv, J. Chen, Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p\/miR-107-CDK6 pathway in bladder carcinoma. Sci. Rep. 6(1), 30919 (2016). https:\/\/doi.org\/10.1038\/srep30919","journal-title":"Sci. Rep."},{"key":"1216_CR137","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.canlet.2017.06.027","volume":"403","author":"Z Zhong","year":"2017","unstructured":"Z. Zhong, M. Huang, M. Lv et al., Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA\/VEGFR2 signaling pathway. Cancer Lett. 403, 305\u2013317 (2017). https:\/\/doi.org\/10.1016\/j.canlet.2017.06.027","journal-title":"Cancer Lett."},{"issue":"2","key":"1216_CR138","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14737159.2019.1680284","volume":"20","author":"E Kouba","year":"2020","unstructured":"E. Kouba, A. Lopez-Beltran, R. Montironi et al., Expert Rev. Mol. Diagn. 20(2), 255\u2013264 (2020). https:\/\/doi.org\/10.1080\/14737159.2019.1680284","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"67","key":"1216_CR139","doi-asserted-by":"publisher","first-page":"32810","DOI":"10.18632\/oncotarget.25998","volume":"9","author":"T Murakami","year":"2018","unstructured":"T. Murakami, C.M. Yamamoto, T. Akino et al., Bladder cancer detection by urinary extracellular vesicle mRNA analysis. Oncotarget. 9(67), 32810\u201332821 (2018). https:\/\/doi.org\/10.18632\/oncotarget.25998","journal-title":"Oncotarget"},{"issue":"4","key":"1216_CR140","first-page":"118","volume":"42","author":"A Ghoreifi","year":"2024","unstructured":"A. Ghoreifi, S.N. Shishido, S. Sayeed et al., Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma. Urol. Oncol. Semin Orig Investig. 42(4), 118 (2024). e9-118.e17","journal-title":"Urol. Oncol. Semin Orig Investig"},{"key":"1216_CR141","doi-asserted-by":"publisher","first-page":"582843","DOI":"10.3389\/fonc.2020.582843","volume":"10","author":"H Lakshminarayanan","year":"2020","unstructured":"H. Lakshminarayanan, D. Rutishauser, P. Schraml, H. Moch, H.A. Bolck, Liquid Biopsies in Renal Cell Carcinoma-Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. Front. Oncol. 10, 582843 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.582843","journal-title":"Front. Oncol."},{"issue":"6","key":"1216_CR142","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.euo.2019.09.002","volume":"2","author":"AW Hahn","year":"2019","unstructured":"A.W. Hahn, Z. Klaassen, N. Agarwal et al., First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur. Urol. Oncol. 2(6), 708\u2013715 (2019). https:\/\/doi.org\/10.1016\/j.euo.2019.09.002","journal-title":"Eur. Urol. Oncol."},{"issue":"8","key":"1216_CR143","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1016\/j.asjsur.2024.02.002","volume":"47","author":"L Cao","year":"2024","unstructured":"L. Cao, W. Yang, X. Zhao, Z. Chen, Diagnostic and prognostic value of circulating tumor cells in renal cell cancer: A systematic review and meta-analysis. Asian J. Surg. 47(8), 3425\u20133434 (2024). https:\/\/doi.org\/10.1016\/j.asjsur.2024.02.002","journal-title":"Asian J. Surg."},{"issue":"9","key":"1216_CR144","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/onco.13842","volume":"26","author":"U Basso","year":"2021","unstructured":"U. Basso, A. Facchinetti, E. Rossi et al., Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist. 26(9), 740\u2013750 (2021). https:\/\/doi.org\/10.1002\/onco.13842","journal-title":"Oncologist"},{"issue":"1","key":"1216_CR145","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12957-021-02268-5","volume":"19","author":"J Song","year":"2021","unstructured":"J. Song, Z. Yu, B. Dong et al., Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma. World J. Surg. Oncol. 19(1), 156 (2021). https:\/\/doi.org\/10.1186\/s12957-021-02268-5","journal-title":"World J. Surg. Oncol."},{"issue":"6","key":"1216_CR146","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11934-021-01050-0","volume":"22","author":"M Marchioni","year":"2021","unstructured":"M. Marchioni, J.G. Rivas, A. Autran et al., Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. Curr. Urol. Rep. 22(6), 31 (2021). https:\/\/doi.org\/10.1007\/s11934-021-01050-0","journal-title":"Curr. Urol. Rep."},{"issue":"8","key":"1216_CR147","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1055-9965.EPI-08-1178","volume":"18","author":"K Bluemke","year":"2009","unstructured":"K. Bluemke, U. Bilkenroth, A. Meye et al., Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Renal Cell Carcinoma Correlates with Prognosis. Cancer Epidemiol. Biomarkers Prev. 18(8), 2190\u20132194 (2009). https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-1178","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"7","key":"1216_CR148","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/cncr.21775","volume":"106","author":"A Buchner","year":"2006","unstructured":"A. Buchner, R. Riesenberg, I. Kotter, A. Hofstetter, C. Stief, R. Oberneder, Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma. Cancer. 106(7), 1514\u20131520 (2006). https:\/\/doi.org\/10.1002\/cncr.21775","journal-title":"Cancer"},{"issue":"4","key":"1216_CR149","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/15384047.2018.1537576","volume":"20","author":"ZL Wang","year":"2019","unstructured":"Z.L. Wang, P. Zhang, H.C. Li et al., Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC. Cancer Biol. Ther. 20(4), 505\u2013512 (2019). https:\/\/doi.org\/10.1080\/15384047.2018.1537576","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"1216_CR150","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00262-017-2064-1","volume":"67","author":"J Wang","year":"2018","unstructured":"J. Wang, L. Liu, Y. Qu et al., HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. Cancer Immunol. Immunother. 67(1), 79\u201387 (2018). https:\/\/doi.org\/10.1007\/s00262-017-2064-1","journal-title":"Cancer Immunol. Immunother"},{"issue":"9","key":"1216_CR151","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/1878-0261.12931","volume":"15","author":"RM Bade","year":"2021","unstructured":"R.M. Bade, J.L. Schehr, H. Emamekhoo et al., Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. Mol. Oncol. 15(9), 2330\u20132344 (2021). https:\/\/doi.org\/10.1002\/1878-0261.12931","journal-title":"Mol. Oncol."},{"issue":"29","key":"1216_CR152","doi-asserted-by":"publisher","first-page":"20467","DOI":"10.18632\/oncotarget.24943","volume":"9","author":"Y Yamamoto","year":"2018","unstructured":"Y. Yamamoto, M. Uemura, K. Nakano et al., Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget. 9(29), 20467\u201320475 (2018). https:\/\/doi.org\/10.18632\/oncotarget.24943","journal-title":"Oncotarget"},{"key":"1216_CR153","doi-asserted-by":"crossref","unstructured":"M. Li, Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. (2023)","DOI":"10.1186\/s12943-023-01745-7"},{"issue":"8","key":"1216_CR154","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41436-020-0801-x","volume":"22","author":"K Lasseter","year":"2020","unstructured":"K. Lasseter, A.H. Nassar, L. Hamieh et al., Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genet. Med. 22(8), 1366\u20131373 (2020). https:\/\/doi.org\/10.1038\/s41436-020-0801-x","journal-title":"Genet. Med."},{"issue":"2","key":"1216_CR155","doi-asserted-by":"publisher","first-page":"100999","DOI":"10.1016\/j.tranon.2020.100999","volume":"14","author":"AS Salinas-S\u00e1nchez","year":"2021","unstructured":"A.S. Salinas-S\u00e1nchez, D.C. Garc\u00eda-Olmo, C. Mart\u00ednez-Sanchiz et al., Clinical value of perioperative levels of DNA and mRNA in plasma of patients with renal cell carcinoma. Transl Oncol. 14(2), 100999 (2021). https:\/\/doi.org\/10.1016\/j.tranon.2020.100999","journal-title":"Transl Oncol."},{"issue":"1","key":"1216_CR156","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1038\/s41598-021-85099-4","volume":"11","author":"YJ Kim","year":"2021","unstructured":"Y.J. Kim, Y. Kang, J.S. Kim et al., Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma. Sci. Rep. 11(1), 5600 (2021). https:\/\/doi.org\/10.1038\/s41598-021-85099-4","journal-title":"Sci. Rep."},{"issue":"3","key":"1216_CR157","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000351409","volume":"91","author":"J Wan","year":"2013","unstructured":"J. Wan, L. Zhu, Z. Jiang, K. Cheng, Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma. Urol. Int. 91(3), 273\u2013278 (2013). https:\/\/doi.org\/10.1159\/000351409","journal-title":"Urol. Int."},{"key":"1216_CR158","doi-asserted-by":"publisher","first-page":"763790","DOI":"10.3389\/fonc.2021.763790","volume":"11","author":"Y Peng","year":"2021","unstructured":"Y. Peng, W. Mei, K. Ma, C. Zeng, Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives. Front. Oncol. 11, 763790 (2021). https:\/\/doi.org\/10.3389\/fonc.2021.763790","journal-title":"Front. Oncol."},{"issue":"5","key":"1216_CR159","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11255-018-1841-x","volume":"50","author":"Y Mytsyk","year":"2018","unstructured":"Y. Mytsyk, V. Dosenko, Y. Borys et al., MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Int. Urol. Nephrol. 50(5), 851\u2013859 (2018). https:\/\/doi.org\/10.1007\/s11255-018-1841-x","journal-title":"Int. Urol. Nephrol."},{"issue":"1","key":"1216_CR160","doi-asserted-by":"publisher","first-page":"21290","DOI":"10.1038\/s41598-020-77774-9","volume":"10","author":"G Cochetti","year":"2020","unstructured":"G. Cochetti, L. Cari, G. Nocentini et al., Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci. Rep. 10(1), 21290 (2020). https:\/\/doi.org\/10.1038\/s41598-020-77774-9","journal-title":"Sci. Rep."},{"issue":"4","key":"1216_CR161","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s12253-020-00842-y","volume":"26","author":"G Huang","year":"2020","unstructured":"G. Huang, X. Li, Z. Chen et al., A Three-microRNA Panel in Serum: Serving as a Potential Diagnostic Biomarker for Renal Cell Carcinoma. Pathol. Oncol. Res. 26(4), 2425\u20132434 (2020). https:\/\/doi.org\/10.1007\/s12253-020-00842-y","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"1216_CR162","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13046-020-01600-3","volume":"39","author":"G Outeiro-Pinho","year":"2020","unstructured":"G. Outeiro-Pinho, D. Barros-Silva, E. Aznar et al., MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. J. Exp. Clin. Cancer Res. 39(1), 98 (2020). https:\/\/doi.org\/10.1186\/s13046-020-01600-3","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"1216_CR163","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13148-018-0444-9","volume":"10","author":"FG Heinemann","year":"2018","unstructured":"F.G. Heinemann, Y. Tolkach, M. Deng et al., Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin. Epigenetics. 10(1), 11 (2018). https:\/\/doi.org\/10.1186\/s13148-018-0444-9","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"1216_CR164","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1442-2042.2010.02454.x","volume":"17","author":"T Okegawa","year":"2010","unstructured":"T. Okegawa, K. Hayashi, H. Hara, K. Nutahara, E. Higashihara, Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int. J. Urol. 17(3), 254\u2013258 (2010). https:\/\/doi.org\/10.1111\/j.1442-2042.2010.02454.x","journal-title":"Int. J. Urol."},{"issue":"2","key":"1216_CR165","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14737159.2019.1680284","volume":"20","author":"E Kouba","year":"2020","unstructured":"E. Kouba, A. Lopez-Beltran, R. Montironi et al., Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev. Mol. Diagn. 20(2), 255\u2013264 (2020). https:\/\/doi.org\/10.1080\/14737159.2019.1680284","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"1","key":"1216_CR166","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1194\/jlr.R084343","volume":"60","author":"T Skotland","year":"2019","unstructured":"T. Skotland, N.P. Hessvik, K. Sandvig, A. Llorente, Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J. Lipid Res. 60(1), 9\u201318 (2019). https:\/\/doi.org\/10.1194\/jlr.R084343","journal-title":"J. Lipid Res."},{"issue":"12","key":"1216_CR167","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3390\/diagnostics12122897","volume":"12","author":"C Seneviratne","year":"2022","unstructured":"C. Seneviratne, A.C. Shetty, X. Geng et al., A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer. Diagnostics. 12(12), 2897 (2022). https:\/\/doi.org\/10.3390\/diagnostics12122897","journal-title":"Diagnostics"},{"key":"1216_CR168","doi-asserted-by":"crossref","unstructured":"A. Hallermayr, T.M. Neuhann, V. Steinke-Lange et al., Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants. Front. Oncol. 12 (2022). Accessed February 28, 2023. https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1014592","DOI":"10.3389\/fonc.2022.1014592"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01216-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:27:34Z","timestamp":1776698854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01216-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":168,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01216-3","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}